Figures & data
Figure 1 Study design (JSWOG-C2).
![Figure 1 Study design (JSWOG-C2).](/cms/asset/4328eaec-9266-4e5a-bdc6-7fa52ff68d7b/dddt_a_12173030_f0001_b.jpg)
Table 1 Patient characteristics (N=86)
Figure 3 CONSORT diagram for this study.
Abbreviation: CONSORT, consolidated standards of reporting trials.
![Figure 3 CONSORT diagram for this study.](/cms/asset/3c008c39-268b-406b-a2b0-381e422ecfa1/dddt_a_12173030_f0003_b.jpg)
Table 2 Proportion of patients completing treatment and dose of oxaliplatin in the treatments
Table 3 Adverse events
Figure 4 Frequency of neurotoxicity at four points: baseline and months 1.5, 3, and 6 after induction of adjuvant chemotherapy.
![Figure 4 Frequency of neurotoxicity at four points: baseline and months 1.5, 3, and 6 after induction of adjuvant chemotherapy.](/cms/asset/13b172e2-c7cc-4bfb-8a8f-c71cb2f7ec37/dddt_a_12173030_f0004_b.jpg)
Table 4 Correlation between PNQ and CTCAE by Spearman’s correlation coefficient
Figure 5 PSN during oxaliplatin treatment and at month 6.
![Figure 5 PSN during oxaliplatin treatment and at month 6.](/cms/asset/1612d303-9c4d-45c6-84d0-ccccd40f6025/dddt_a_12173030_f0005_b.jpg)